SHP2 Tyrosine Phosphatase Converts Parafibromin/Cdc73 from a Tumor Suppressor to an Oncogenic Driver

Molecular Cell

Volumn 43, Issue 1, 2011, Pages 45-56

  Takahashi, Atsushi ^a,b   Tsutsumi, Ryouhei ^a   Kikuchi, Ippei ^a   Obuse, Chikashi ^b   Saito, Yasuhiro ^a   Seidi, Azadeh ^a   Karisch, Robert ^c,d   Fernandez, Minerva ^c,d   Cho, Taewoo ^c,d   Ohnishi, Naomi ^b   Rozenblatt Rosen, Orit ^e   Meyerson, Matthew ^e,f   Neel, Benjamin G ^c,d   Hatakeyama, Masanori ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; HISTONE METHYLTRANSFERASE; MYC PROTEIN; PARAFIBROMIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; THROMBOCYTE ACTIVATING FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; DEPHOSPHORYLATION; GENE ACTIVATION; GENE CONVERSION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

ANIMALS; BETA CATENIN; CELL NUCLEUS; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIN D1; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; TYROSINE; WNT PROTEINS;

EID: 79959861920     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2011.05.014     Document Type: Article

References (50)

1. Agazie Y.M., Hayman M.J. Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates. J. Biol. Chem. 2003, 278:13952-13958.
2. Alfieri C.M., Cheek J., Chakraborty S., Yutzey K.E. Wnt signaling in heart valve development and osteogenic gene induction. Dev. Biol. 2010, 338:127-135.
3. Aoki Y., Niihori T., Narumi Y., Kure S., Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum. Mutat. 2008, 29:992-1006.
4. Araki T., Mohi M.G., Ismat F.A., Bronson R.T., Williams I.R., Kutok J.L., Yang W., Pao L.I., Gilliland D.G., Epstein J.A., Neel B.G. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 2004, 10:849-857.
5. Bentires-Alj M., Gil S.G., Chan R., Wang Z.C., Wang Y., Imanaka N., Harris L.N., Richardson A., Neel B.G., Gu H. A role for the scaffolding adapter GAB2 in breast cancer. Nat. Med. 2006, 12:114-121.
6. Caca K., Kolligs F.T., Ji X., Hayes M., Qian J., Yahanda A., Rimm D.L., Costa J., Fearon E.R. Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ. 1999, 10:369-376.
7. Carpten J.D., Robbins C.M., Villablanca A., Forsberg L., Presciuttini S., Bailey-Wilson J., Simonds W.F., Gillanders E.M., Kennedy A.M., Chen J.D., et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. 2002, 32:676-680.
8. Chan R.J., Feng G.S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007, 109:862-867.
9. Chaudhary K., Deb S., Moniaux N., Ponnusamy M.P., Batra S.K. Human RNA polymerase II-associated factor complex: dysregulation in cancer. Oncogene 2007, 26:7499-7507.
10. Chen Y., Alman B.A. Wnt pathway, an essential role in bone regeneration. J. Cell. Biochem. 2009, 106:353-362.
11. Cooper L.J.N., Shannon K.M., Loken M.R., Weaver M., Stephens K., Sievers E.L. Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood 2000, 96:2310-2313.
12. Cordeddu V., Di Schiavi E., Pennacchio L.A., Ma'ayan A., Sarkozy A., Fodale V., Cecchetti S., Cardinale A., Martin J., Schackwitz W., et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat. Genet. 2009, 41:1022-1026.
13. Dreijerink K.M., Hoppener J.W., Timmers H.M., Lips C.J. Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation. Nat. Clin. Pract. Endocrinol. Metab. 2006, 2:562-570.
14. Gregorieff A., Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev. 2005, 19:877-890.
15. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat. Rev. Cancer 2004, 4:688-694.
16. Higashi H., Tsutsumi R., Muto S., Sugiyama T., Azuma T., Asaka M., Hatakeyama M. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002, 295:683-686.
17. Higuchi M., Tsutsumi R., Higashi H., Hatakeyama M. Conditional gene silencing utilizing the lac repressor reveals a role of SHP-2 in cagA-positive Helicobacter pylori pathogenicity. Cancer Sci. 2004, 95:442-447.
18. Iwata T., Mizusawa N., Taketani Y., Itakura M., Yoshimoto K. Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen. Oncogene 2007, 26:6176-6183.
19. Jaehning J.A. The Paf1 complex: platform or player in RNA polymerase II transcription?. Biochim. Biophys. Acta 2010, 1799:379-388.
20. Jakob S., Schroeder P., Lukosz M., Büchner N., Spyridopoulos I., Altschmied J., Haendeler J. Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase. J. Biol. Chem. 2008, 283:33155-33161.
21. Janssen K.P., Alberici P., Fsihi H., Gaspar C., Breukel C., Franken P., Rosty C., Abal M., El Marjou F., Smits R., et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006, 131:1096-1109.
22. Johnson Hamlet M.R., Perkins L.A. Analysis of corkscrew signaling in the Drosophila epidermal growth factor receptor pathway during myogenesis. Genetics 2001, 159:1073-1087.
23. Kim J., Guermah M., Roeder R.G. The human PAF1 complex acts in chromatin transcription elongation both independently and cooperatively with SII/TFIIS. Cell 2010, 140:491-503.
24. Kinch M.S., Clark G.J., Der C.J., Burridge K. Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. J. Cell Biol. 1995, 130:461-471.
25. Lilien J., Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of β-catenin. Curr. Opin. Cell Biol. 2005, 17:459-465.
26. Lin L., Zhang J.H., Panicker L.M., Simonds W.F. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. Proc. Natl. Acad. Sci. USA 2008, 105:17420-17425.
27. Luo F., Brooks D.G., Ye H., Hamoudi R., Poulogiannis G., Patek C.E., Winton D.J., Arends M.J. Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int. J. Exp. Pathol. 2009, 90:558-574.
28. MacDonald B.T., Tamai K., He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev. Cell 2009, 17:9-26.
29. Miyamoto D., Miyamoto M., Takahashi A., Yomogita Y., Higashi H., Kondo S., Hatakeyama M. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 2008, 27:3508-3515.
30. Mohi M.G., Neel B.G. The role of Shp2 (PTPN11) in cancer. Curr. Opin. Genet. Dev. 2007, 17:23-30.
31. Mosimann C., Hausmann G., Basler K. Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with β-catenin/Armadillo. Cell 2006, 125:327-341.
32. Neel B.G., Gu H., Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 2003, 28:284-293.
33. Nemeth M.J., Bodine D.M. Regulation of hematopoiesis and the hematopoietic stem cell niche by Wnt signaling pathways. Cell Res. 2007, 17:746-758.
34. Newey P.J., Bowl M.R., Thakker R.V. Parafibromin-functional insights. J. Intern. Med. 2009, 266:84-98.
35. Phelps R.A., Chidester S., Dehghanizadeh S., Phelps J., Sandoval I.T., Rai K., Broadbent T., Sarkar S., Burt R.W., Jones D.A. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 2009, 137:623-634.
36. Rozenblatt-Rosen O., Hughes C.M., Nannepaga S.J., Shanmugam K.S., Copeland T.D., Guszczynski T., Resau J.H., Meyerson M. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol. Cell. Biol. 2005, 25:612-620.
37. Saadat I., Higashi H., Obuse C., Umeda M., Murata-Kamiya N., Saito Y., Lu H., Ohnishi N., Azuma T., Suzuki A., et al. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature 2007, 447:330-333.
38. Sansom O.J., Meniel V., Wilkins J.A., Cole A.M., Oien K.A., Marsh V., Jamieson T.J., Guerra C., Ashton G.H., Barbacid M., Clarke A.R. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc. Natl. Acad. Sci. USA 2006, 103:14122-14127.
39. Staal F.J.T., Sen J.M. The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis. Eur. J. Immunol. 2008, 38:1788-1794.
40. Tartaglia M., Mehler E.L., Goldberg R., Zampino G., Brunner H.G., Kremer H., van der Burgt I., Crosby A.H., Ion A., Jeffery S., et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 2001, 29:465-468.
41. Tidyman W.E., Rauen K.A. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr. Opin. Genet. Dev. 2009, 19:230-236.
42. Townsley F.M., Cliffe A., Bienz M. Pygopus and Legless target Armadillo/β-catenin to the nucleus to enable its transcriptional co-activator function. Nat. Cell Biol. 2004, 6:626-633.
43. van Amerongen R., Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009, 136:3205-3214.
44. Wang P., Bowl M.R., Bender S., Peng J., Farber L., Chen J., Ali A., Zhang Z., Alberts A.S., Thakker R.V., et al. Parafibromin, a component of the human PAF complex, regulates growth factors and is required for embryonic development and survival in adult mice. Mol. Cell. Biol. 2008, 28:2930-2940.
45. Woodard G.E., Lin L., Zhang J.H., Agarwal S.K., Marx S.J., Simonds W.F. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 2005, 24:1272-1276.
46. Wu T.R., Hong Y.K., Wang X.D., Ling M.Y., Dragoi A.M., Chung A.S., Campbell A.G., Han Z.Y., Feng G.S., Chin Y.E. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J. Biol. Chem. 2002, 277:47572-47580.
47. Xu R., Yu Y., Zheng S., Zhao X., Dong Q., He Z., Liang Y., Lu Q., Fang Y., Gan X., et al. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood 2005, 106:3142-3149.
48. Yang W., Klaman L.D., Chen B., Araki T., Harada H., Thomas S.M., George E.L., Neel B.G. An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev. Cell 2006, 10:317-327.
49. Yang Y.J., Han J.W., Youn H.D., Cho E.J. The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. Nucleic Acids Res. 2010, 38:382-390.
50. Zhang C., Kong D., Tan M.H., Pappas D.L., Wang P.F., Chen J., Farber L., Zhang N., Koo H.M., Weinreich M., et al. Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem. Biophys. Res. Commun. 2006, 350:17-24.